- Home
- BIIB vs CUK Comparison
BIIB vs CUK Comparison
Compare BIIB & CUK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CUK
- Stock Information
- Founded
- BIIB 1978
- CUK 1972
- Country
- BIIB United States
- CUK United States
- Employees
- BIIB N/A
- CUK N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CUK Marine Transportation
- Sector
- BIIB Health Care
- CUK Consumer Discretionary
- Exchange
- BIIB Nasdaq
- CUK Nasdaq
- Market Cap
- BIIB 18.8B
- CUK 26.6B
- IPO Year
- BIIB 1991
- CUK 2000
- Fundamental
- Price
- BIIB $124.99
- CUK $26.95
- Analyst Decision
- BIIB Buy
- CUK Buy
- Analyst Count
- BIIB 27
- CUK 15
- Target Price
- BIIB $188.17
- CUK $29.13
- AVG Volume (30 Days)
- BIIB 1.2M
- CUK 2.6M
- Earning Date
- BIIB 07-31-2025
- CUK 06-24-2025
- Dividend Yield
- BIIB N/A
- CUK N/A
- EPS Growth
- BIIB 26.39
- CUK 160.22
- EPS
- BIIB 10.12
- CUK 1.84
- Revenue
- BIIB $9,816,400,000.00
- CUK $25,972,000,000.00
- Revenue This Year
- BIIB N/A
- CUK $7.03
- Revenue Next Year
- BIIB N/A
- CUK $3.43
- P/E Ratio
- BIIB $12.35
- CUK $15.15
- Revenue Growth
- BIIB 1.59
- CUK 10.82
- 52 Week Low
- BIIB $110.04
- CUK $12.65
- 52 Week High
- BIIB $236.48
- CUK $27.59
- Technical
- Relative Strength Index (RSI)
- BIIB 41.14
- CUK 70.31
- Support Level
- BIIB $132.37
- CUK $26.14
- Resistance Level
- BIIB $137.84
- CUK $26.98
- Average True Range (ATR)
- BIIB 4.16
- CUK 0.63
- MACD
- BIIB -0.68
- CUK -0.08
- Stochastic Oscillator
- BIIB 7.82
- CUK 77.45
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CUK Carnival Plc ADS ADS
Carnival is the largest global cruise company, with more than 90 ships in service at the end of fiscal 2024. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe. It's currently folding its P&O Australia brand into Carnival. The firm also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted 14 million guests in 2024.